pentigide: synthetic peptide derived from the Fc region of human lgE; RN given refers to the all-L-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 162960 |
| CHEBI ID | 135842 |
| SCHEMBL ID | 29861 |
| MeSH ID | M0120080 |
| Synonym |
|---|
| pentigetide |
| pentyde |
| pentyde (tn) |
| 62087-72-3 |
| pentigetide (usan/inn) |
| D05423 |
| CHEBI:135842 |
| asp-ser-asp-pro-arg |
| human ige pentapeptide |
| pentapeptide dsdpr |
| ige pentapeptide |
| pentigetida [inn-spanish] |
| unii-yg3j18t1ux |
| pentigetidum [inn-latin] |
| l-arginine, n(sup 2)-(1-(n-(n-l-alpha-aspartyl-l-seryl)-l-alpha-aspartyl)-l-prolyl)- |
| n(sup 2)-(1-(n-(n-l-alpha-aspartyl-l-seryl)-l-alpha-aspartyl)-l-prolyl)-l-arginine |
| pentigetid |
| pentigetida |
| pentigide |
| pentigetidum |
| yg3j18t1ux , |
| pentigetide [usan:inn] |
| hamburger pentapeptide |
| pentapeptide-dsdpr |
| l-arginine, n(sup 2)-(1-(n-(n-l-.alpha.-aspartyl-l-seryl)-l-.alpha.-aspartyl)-l-prolyl)- |
| l-.alpha.-aspartyl-l-seryl-l-.alpha.-aspartyl-l-prolyl-l-arginine |
| pentigetide [inn] |
| n(sup 2)-(1-(n-(n-l-.alpha.-aspartyl-l-seryl)-l-.alpha.-aspartyl)-l-prolyl)-l-arginine |
| pentigetide [mi] |
| pentigetide [usan] |
| SCHEMBL29861 |
| (2s)-2-{[(2s)-1-[(2s)-2-[(2s)-2-[(2s)-2-amino-3-carboxypropanamido]-3-hydroxypropanamido]-3-carboxypropanoyl]pyrrolidin-2-yl]formamido}-5-[(diaminomethylidene)amino]pentanoic acid |
| aspartylserylaspartylprolylarginine |
| (s)-2-((s)-1-((s)-2-((s)-2-((s)-2-amino-3-carboxypropanamido)-3-hydroxypropanamido)-3-carboxypropanoyl)pyrrolidine-2-carboxamido)-5-guanidinopentanoic acid |
| l-aspartyl-l-seryl-l-aspartyl-l-prolyl-l-arginine |
| KQDIGHIVUUADBZ-PEDHHIEDSA-N |
| n~2~-[{1-[2-({2-[(2-amino-3-carboxy-1-hydroxypropylidene)amino]-1,3-dihydroxypropylidene}amino)-3-carboxypropanoyl]pyrrolidin-2-yl}(hydroxy)methylidene]arginine |
| DTXSID30977675 |
| Q27294502 |
| (2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid |
| HY-P3746 |
| CS-0620399 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The incidence and types of adverse experiences were similar between treatment groups and there were no reports of sedation or fatigue in the pentigetide group." | ( Pentigetide nasal solution: a multicenter study evaluating efficacy and safety in patients with seasonal allergic rhinitis. Daigle, A; Findlay, S; Haddad, Z; Hampel, F; Kniker, W; Mansmann, HC; Ratner, P; Rosen, J; Ziering, R, 1991) | 0.28 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety, dosage and efficacy of human IgE pentapeptide (HEPP) was evaluated in 12 patients with IgE-mediated atopic disease." | ( Safety and efficacy of human IgE pentapeptide. Cohen, GA; Hamburger, RN; O'Connor, RD, 1984) | 0.27 |
| Class | Description |
|---|---|
| oligopeptide | A peptide containing a relatively small number of amino acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (60.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (30.77%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (61.54%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||